SELLAS Life Sciences Group, Inc. Business Combination, Consideration Transferred
SELLAS Life Sciences Group, Inc. (SLS) reported Business Combination, Consideration Transferred of $12.52 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-04-13.
Discontinued › Notes › Business Combinations › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation
us-gaap:BusinessCombinationConsiderationTransferred1 · last filed 2019-03-22
- SELLAS Life Sciences Group, Inc. business combination, consideration transferred for fiscal 2017 was $12.52M.
| Period end | Business Combination, Consideration Transferred | Business Combination, Consideration Transferred 12 month |
|---|---|---|
| 2017-12-31 | $12.52M 10-K · filed 2018-04-13 | |
| 2017-12-29 | $12.52M 10-K · filed 2019-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |